Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Behcet's patients: drug TA-650 targets tough lesions

NCT ID NCT01532570

Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the drug TA-650 (infliximab) in 18 people with Behcet's disease who had hard-to-treat lesions. The drug was given by IV every few weeks for nearly a year. The goal was to see if symptoms and signs of inflammation could be completely controlled. The trial is complete, but results are not yet widely available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TA-650 (infliximab, a biologic drug that blocks inflammation)
What this could lead to
If it works, this could point toward a treatment option for people with Behcet's disease who have severe lesions not helped by standard therapies.
What could go wrong
This is a small, completed Phase 3 trial with only 18 participants, so results may not apply to everyone. The drug is already approved for other conditions, but its benefits for Behcet's special lesions remain uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

18 people

The number who actually took part.

Start date

Jan 2012

Finished

May 2014

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who were diagnosed with the complete or incomplete type of Behcet's disease according to "The criteria for a diagnosis of Behcet's disease, Ministry of Health, Labour and Welfare in Japan (partially revised in 2010)" * Patients who have special lesions despite having received conventional treatments for special lesions, or patients who cannot receive conventional treatments due to intolerability. * Patients who have clinical symptoms associated with each special lesions. Exclusion Criteria: * Patients with intestinal, neuro-, vascular Behcet's disease in whom a differential diagnosis of each Behcet's disease from other conditions． * Patients who have received treatment with infliximab within 1 year before enrollment for another purpose than treating special lesions; or patients whose previous treatment with infliximab was discontinued due to adverse events. * Patients who had participated in another clinical study and had received a study drug within 12 weeks before giving acquirement.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Behcet syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Behcet disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Behcet syndrome Behcet's disease Neuro-Behcet's disease

Contacts and locations

Locations

  • Investigational site

    Chūbu, Japan

  • Investigational site

    Hokkaido, Japan

  • Investigational site

    Kanto, Japan

  • Investigational site

    Kinki, Japan

  • Investigational site

    Kyusyu, Japan

  • Investigational site

    Tōhoku, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.